Expanding offerings to include CNS gene therapy, diagnostics, and biomarker services
Iron Horse Diagnostics has changed its name to nVector to reflect the company’s expanded focus. The company’s next generation gene therapy technology is poised to enable revolutionary treatments for central nervous system (CNS) diseases such as Alzheimer’s, Parkinson’s, ALS, and Traumatic Brain Injury.
nVector’s leading-edge platform includes gene therapy development, delivery and diagnostics to accelerate existing initiatives and quick-launch new initiatives. To help facilitate this growth, the company has brought on board Fredric Manfredsson, Ph.D. as Chief Scientific Officer and Ivette Sandoval, Ph.D., as VP of Vector Development.
The nVector Adeno-Associated Virus platform features the first technology to target brain glia (immune) and neuron cells by type and offers better distribution throughout the spinal cord and brain from a single injection. In addition, its 100 MM novel capsid library can support a wide array of CNS gene therapy initiatives.
Along with the 100M plus capsid library, nVector’s products and services currently include therapeutic vectors to accelerate development of treatments for ALS, Huntington’s and Parkinson’s, the most advanced clinical assays for ALS, and development of customized biomarker assays.
Iron Horse was founded in 2012 by Robert Bowser, Ph.D. to create breakthrough diagnostic tests in neurologic disorders with high-unmet medical need. The company has received funding from The National Institute of Health, The ALS Association, The Arizona Commerce Authority and Biogen. Results have been published in numerous scientific publications including, Journal of the Neurological Sciences. The company’s neurologic diagnostic innovations also include a simple blood based TBI/Concussion diagnostic test, as well as biomarker assay services for some of the most innovative companies in the U.S.
For further information, contact:
Michael Hull
President
nVector
michael.hull@nvector.com